2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, APL, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5185 Efficacy of sorafenib combined with venetoclax and azacitidine in newly diagnosed FLT3-ITD-mutant acute myeloid leukemia: Remission efficacy and prognostic influence of post-remission consolidation therapy

Qi Chen, Wenbing Duan2, Jinsong JIA, MD, PhD3, Jing Wang, MD4, Xiaosu Zhao5, Guorui Ruan, PhD6, Ying-Jun Chang7, Xiaojun Huang, MD,PhD8, Hao Jiang9
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
7 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
8 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China
9 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, Peking University, Beijing, China

Introduction

FLT3-ITD mutations are detected in approximately 30% of adult acute myeloid leukemia (AML) and correlate with inferior clinical outcomes when treated with conventional chemotherapy. While triplet combinations incorporating second-generation FLT3 inhibitors plus venetoclax-azacitidine (VA) improve remission depth and survival in unfit patients with FLT3-mutant AML, these agents remain costly and difficult to access in many clinical centers. Sorafenib, an inexpensive first-generation FLT3 tyrosine kinase inhibitor, is widely available across China. However, real-world data evaluating sorafenib plus VA as frontline induction for newly diagnosed FLT3-ITD AML remain limited.

Methods

We consecutively enrolled 45 newly diagnosed FLT3-ITD-mutant adult AML patients receiving sorafenib-VA induction at Peking University People’s Hospital between February 2021 and November 2024. FLT3-ITD allelic ratio and concurrent mutations were detected via capillary electrophoresis PCR and NGS. Induction regimen: sorafenib 400 mg twice daily days 1-21, venetoclax ramped to 400 mg days 1-21, azacitidine 75 mg/m2 days 1-7 per 28-day cycle. Primary endpoint was composite complete remission (CRc, CR/CRi); secondary endpoints comprised multiparameter flow MRD negativity, overall survival (OS), relapse-free survival (RFS), and treatment-related adverse events (AEs). Kaplan-Meier, log-rank, Cox regression, chi-square and Fisher’s exact tests were performed via SPSS and R; two-sided P<0.05 defined statistical significance. This study received institutional ethics approval and complied with the Declaration of Helsinki.

Results

The median age of the cohort was 54 years (range 19-74), with concurrent NPM1 mutations identified in 53.3% of patients. Twenty-five patients harbored high FLT3-ITD allelic ratios and 20 harbored low allelic ratios. Risk stratification by the 2022 ELN criteria categorized 4 patients as favorable-risk, 26 as intermediate-risk, and 15 as adverse-risk. After sorafenib-VA induction, the overall CRc rate reached 95.6% (43/45), and 97.7% of responding patients achieved CRc after a single induction cycle. Six patients who attained remission were lost to follow-up; the remaining 37 patients received subsequent consolidation: 24.3% received sorafenib plus conventional chemotherapy, 27.0% received sustained sorafenib-VA maintenance, and 48.6% proceeded to allo-HSCT after consolidation. MRD negativity rates after two consolidation cycles were similar between the sorafenib-VA maintenance and sorafenib-chemotherapy groups (71.4% versus 72.7%, P =0.932). Patients maintained on sorafenib-VA were substantially older (median age 66 years) compared with those receiving sorafenib-chemotherapy (52 years) and transplant candidates (39 years). The median follow-up duration for evaluable patients was 20.3 months. The 2-year OS and RFS for the entire cohort were 65.3% and 57.3%, respectively. Patients undergoing allo-HSCT exhibited a significantly lower relapse risk relative to those receiving sorafenib-chemotherapy consolidation (P =0.002), with a 2-year RFS of 70.3% (95% CI, 51.5–96.1%). The sorafenib-VA maintenance group, predominantly composed of elderly patients, demonstrated a 2-year OS of 57.1% (95% CI, 30.1-100%) and a 2-year RFS of 64% (95% CI, 37.4–100%), outcomes superior to the chemotherapy consolidation cohort. Multivariate Cox regression identified two independent adverse prognostic factors for RFS: chemotherapy-based consolidation (HR = 5.615, P =0.027) and persistent MRD positivity after two consolidation cycles (P =0.005). Grade≥3 hematologic toxicities, including neutropenia, thrombocytopenia and febrile neutropenia, occurred frequently during induction yet were clinically manageable. No treatment-related mortality was observed.

Conclusion

The sorafenib-VA triplet regimen achieves robust CRc and MRD clearance rates with a favorable safety profile when administered as frontline induction for patients with newly diagnosed FLT3-ITD-mutant AML. Allo-HSCT delivers optimal long-term relapse control for transplant-eligible candidates. For elderly patients or individuals ineligible for allo-HSCT, continuous sorafenib-VA maintenance yields sustained survival benefits superior to sorafenib combined with conventional chemotherapy. Given its low cost and wide availability, sorafenib-VA triplet therapy represents a viable frontline treatment option for FLT3-ITD-mutant AML in resource-limited clinical settings.

Qi Chen: No relevant conflicts of interest to declare.